The role of HGF/c MET signaling pathway in lymphoma
Inappropriate activation of c mesenchymal epithelial transition (MET) the receptor tyrosine kinase (RTK) for hepatocyte growth factor (HGF) has been implicated in tumorigenesis and represented a promising therapeutic target for developing anticancer agents. In contrast to other solid tumors, there are limited data describing the functional role of HGF/c MET signaling pathway in lymphoma. In the current review, we summarize recent findings about the expression, cellular mechanisms/functions, and therapeutic application of HGF/c MET in different types of lymphoma, especially B cell lymphoma, T and NK cell lymphoma, and Hodgkin lymphoma. We also discuss the existing problems and future directions about studying the HGF/c MET pathway in lymphoma cells.
Journal of Hematology Oncology